Quidel Corporation, a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, today announced its entry into agreements with Beckman Coulter resolving their ongoing litigation and providing for the transition of the BNP Business to Beckman Coulter.
Under the agreements, Beckman Coulter will pay Quidel cash payments of between $70 million and $75 million per year through 2029. Read more.
